SG10202109457RA - Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof - Google Patents

Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof

Info

Publication number
SG10202109457RA
SG10202109457RA SG10202109457RA SG10202109457RA SG 10202109457R A SG10202109457R A SG 10202109457RA SG 10202109457R A SG10202109457R A SG 10202109457RA SG 10202109457R A SG10202109457R A SG 10202109457RA
Authority
SG
Singapore
Prior art keywords
vectors
compositions
methods
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
Other languages
English (en)
Inventor
Johannes Langedijk
Benoit Callendret
Jörn Stitz
Frank Wegmann
Anders Krarup
Manen Danielle Van
Jort Vellinga
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG10202109457RA publication Critical patent/SG10202109457RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG10202109457R 2015-12-15 2016-12-15 Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof SG10202109457RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15200138 2015-12-15
EP16194124 2016-10-17

Publications (1)

Publication Number Publication Date
SG10202109457RA true SG10202109457RA (en) 2021-10-28

Family

ID=57737697

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804411TA SG11201804411TA (en) 2015-12-15 2016-12-15 Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG10202109457R SG10202109457RA (en) 2015-12-15 2016-12-15 Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201804411TA SG11201804411TA (en) 2015-12-15 2016-12-15 Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof

Country Status (30)

Country Link
US (3) US10369214B2 (enExample)
EP (3) EP3584252B1 (enExample)
JP (2) JP6510149B2 (enExample)
KR (1) KR20180086207A (enExample)
CN (2) CN114686495A (enExample)
AU (2) AU2016369326B2 (enExample)
BR (1) BR112018011122A2 (enExample)
CA (1) CA3008542C (enExample)
CY (2) CY1122705T1 (enExample)
DK (2) DK3584252T3 (enExample)
EA (1) EA038974B1 (enExample)
ES (2) ES2898271T3 (enExample)
HR (2) HRP20211566T1 (enExample)
HU (2) HUE055916T2 (enExample)
IL (1) IL259942B2 (enExample)
LT (2) LT3584252T (enExample)
MA (3) MA55825A (enExample)
MD (2) MD3584252T2 (enExample)
ME (1) ME03545B (enExample)
MX (2) MX383507B (enExample)
PH (1) PH12018501047A1 (enExample)
PL (2) PL3584252T3 (enExample)
PT (1) PT3390430T (enExample)
RS (2) RS62360B1 (enExample)
SG (2) SG11201804411TA (enExample)
SI (2) SI3390430T1 (enExample)
SM (2) SMT202100623T1 (enExample)
TW (2) TWI707039B (enExample)
WO (1) WO2017102929A1 (enExample)
ZA (1) ZA201803978B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092521A1 (ru) 2014-09-26 2021-05-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
SMT202100623T1 (it) 2015-12-15 2022-01-10 Janssen Vaccines & Prevention Bv Antigeni del virus dell'immunodeficienza umana, vettori, composizioni, e metodi di utilizzo degli stessi
BR112018075785A2 (pt) 2016-06-16 2019-04-02 Janssen Vaccines & Prevention B.V. formulação de vacina para o hiv
CA3035759A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR102513146B1 (ko) 2016-09-15 2023-03-23 얀센 백신스 앤드 프리벤션 비.브이. 삼량체를 안정화하는 hiv 엔벨로프 단백질 돌연변이
CA3066573A1 (en) 2017-06-15 2018-12-20 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
MA49616A (fr) 2017-07-19 2020-05-27 Janssen Vaccines & Prevention Bv Mutations de protéine d'enveloppe du vih stabilisant la forme trimère
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
CN110049995A (zh) * 2017-11-17 2019-07-23 盖立复诊断解决方案公司 哺乳动物表达的新型人类免疫缺陷病毒包膜蛋白抗原
WO2020214203A1 (en) * 2019-04-17 2020-10-22 The Wistar Institute Replication deficient adenoviral vectors for hiv vaccine applications
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
CN114585639A (zh) 2019-11-07 2022-06-03 扬森疫苗与预防公司 蛋白质纯化
CA3182703A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
WO2021249011A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022006095A2 (en) * 2020-06-29 2022-01-06 Duke University Mosaic hiv-1 envelopes to induce adcc responses
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
US20220265813A1 (en) 2021-02-23 2022-08-25 Janssen Vaccines & Prevention B.V. Trimer Stabilizing HIV Envelope Protein Mutation
WO2022272275A1 (en) * 2021-06-25 2022-12-29 Janssen Vaccines & Prevention B.V. Combinations of vaccines and neutralizing antibodies for treating human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2023242155A1 (en) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions and methods for the diagnosis of hiv infection

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
DK1818408T3 (da) 1999-05-17 2011-10-17 Crucell Holland Bv Rekombinant adenovirus af serotypen Ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) * 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
CA2785699A1 (en) * 2001-07-05 2003-01-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CN1602316A (zh) 2001-12-04 2005-03-30 巴法里安诺迪克有限公司 黄病毒ns1亚单位疫苗
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
WO2004044155A2 (en) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
CA2505583C (en) 2002-12-03 2014-07-15 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
EP2363143A3 (en) 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
CA2539021A1 (en) 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
EP2163260B1 (en) 2004-01-23 2017-03-15 MSD Italia S.r.l. Chimpanzee adenovirus vaccine carriers
CA2563396A1 (en) * 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
WO2006002079A2 (en) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
AU2005279799A1 (en) * 2004-08-27 2006-03-09 Emory University Recombinant MVA viruses expressing Clade A/G, Clade B and Clade C modified HIV ENV, GAG and POL genes
AU2005293568B2 (en) 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP2040747A4 (en) 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE
WO2008063331A2 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2008140579A2 (en) 2006-11-17 2008-11-20 New York University Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope
AU2008223951B2 (en) 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
BRPI0921588B1 (pt) * 2008-11-18 2021-12-28 Beth Israel Deaconess Medical Center Vacina compreendendo um polipeptídeo viral e seu método de preparação, kit e uso do polipeptídeo viral
EP3385387B1 (en) 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
CN102711794B (zh) 2010-01-04 2015-11-25 Kj生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
JP5783642B2 (ja) 2010-01-28 2015-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ Ｍｖａの主なゲノム欠失を含むワクシニアウイルス変異体
EP4549461A3 (en) 2010-08-31 2025-08-06 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
ES2676196T3 (es) 2010-12-14 2018-07-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vacunas contra filovirus de adenovirus de serotipo 25 y serotipo 35
EP2701736A1 (en) * 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013040766A1 (zh) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 可诱导针对hiv的广谱免疫应答的方法和疫苗
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
CA3200425A1 (en) 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
KR102020758B1 (ko) 2013-01-07 2019-09-11 베쓰 이스라엘 디코니스 메디칼 센터 인크 안정화된 사람 면역결핍 바이러스 (ｈｉｖ) 외피 (ｅｎｖ) 삼량체 백신 및 이의 사용 방법
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10716845B2 (en) * 2013-10-04 2020-07-21 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
US9750801B2 (en) * 2014-02-28 2017-09-05 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
EP3189067B1 (en) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
EA202092521A1 (ru) 2014-09-26 2021-05-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3271729B1 (en) * 2015-03-18 2020-09-23 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
SMT202100623T1 (it) 2015-12-15 2022-01-10 Janssen Vaccines & Prevention Bv Antigeni del virus dell'immunodeficienza umana, vettori, composizioni, e metodi di utilizzo degli stessi
BR112018075785A2 (pt) 2016-06-16 2019-04-02 Janssen Vaccines & Prevention B.V. formulação de vacina para o hiv
CA3035759A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR102513146B1 (ko) 2016-09-15 2023-03-23 얀센 백신스 앤드 프리벤션 비.브이. 삼량체를 안정화하는 hiv 엔벨로프 단백질 돌연변이
DE102018124348A1 (de) 2018-10-02 2020-04-02 Haver & Boecker Ohg Füllkasten und Verfahren zum Füllen von Gebinden

Also Published As

Publication number Publication date
SI3390430T1 (sl) 2019-12-31
RS62360B1 (sr) 2021-10-29
DK3584252T3 (da) 2021-11-15
IL259942B2 (en) 2023-04-01
AU2016369326B2 (en) 2019-02-21
EP3584252B1 (en) 2021-08-25
SI3584252T1 (sl) 2021-11-30
MA47522B1 (fr) 2021-11-30
CN114686495A (zh) 2022-07-01
SG11201804411TA (en) 2018-06-28
JP6510149B2 (ja) 2019-05-08
RS59447B1 (sr) 2019-11-29
US10369214B2 (en) 2019-08-06
PL3390430T3 (pl) 2020-03-31
HUE055916T2 (hu) 2021-12-28
EP3390430A1 (en) 2018-10-24
MD3584252T2 (ro) 2022-01-31
EP3584252A1 (en) 2019-12-25
MX383507B (es) 2025-03-14
CY1122705T1 (el) 2021-03-12
TW201734210A (zh) 2017-10-01
ZA201803978B (en) 2021-05-26
PT3390430T (pt) 2019-11-20
ES2898271T3 (es) 2022-03-04
JP2019505188A (ja) 2019-02-28
CN108368157A (zh) 2018-08-03
SMT201900629T1 (it) 2020-01-14
US20190321462A1 (en) 2019-10-24
IL259942A (en) 2018-07-31
BR112018011122A2 (pt) 2018-11-21
MA44059B1 (fr) 2019-11-29
PL3584252T3 (pl) 2022-01-10
PH12018501047A1 (en) 2018-12-17
US11896663B2 (en) 2024-02-13
TWI792091B (zh) 2023-02-11
JP2019146574A (ja) 2019-09-05
EP3390430B1 (en) 2019-08-28
TW202106701A (zh) 2021-02-16
EP3964569A1 (en) 2022-03-09
MX2018007198A (es) 2018-08-01
EA201891415A8 (ru) 2019-10-31
MA44059A (fr) 2018-10-24
US20170165355A1 (en) 2017-06-15
MA47522A (fr) 2021-05-05
LT3390430T (lt) 2019-11-25
HRP20211566T1 (hr) 2022-03-04
IL259942B (en) 2022-12-01
CA3008542A1 (en) 2017-06-22
CA3008542C (en) 2020-06-02
SMT202100623T1 (it) 2022-01-10
CN108368157B (zh) 2022-04-15
MX2021006931A (es) 2021-07-07
AU2016369326A1 (en) 2018-06-07
MD3390430T2 (ro) 2019-12-31
JP6959289B2 (ja) 2021-11-02
ME03545B (me) 2020-07-20
US10973907B2 (en) 2021-04-13
AU2019203468B2 (en) 2020-05-21
HRP20191902T1 (hr) 2020-01-24
EA201891415A1 (ru) 2018-11-30
ES2753854T3 (es) 2020-04-14
MA55825A (fr) 2022-03-09
KR20180086207A (ko) 2018-07-30
LT3584252T (lt) 2021-09-27
TWI707039B (zh) 2020-10-11
US20210220468A1 (en) 2021-07-22
DK3390430T3 (da) 2019-11-18
HUE045993T2 (hu) 2020-01-28
CY1125387T1 (el) 2023-03-24
AU2019203468A1 (en) 2019-06-06
EA038974B1 (ru) 2021-11-17
WO2017102929A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
ZA201803783B (en) Human immunodeficiency virus neutralizing antibodies
IL257628A (en) Methods and compositions for stealth virus antibody vectors
IL263818A (en) Antibodies against Zika virus and methods of use
ZA201703163B (en) Rna guided eradication of human jc virus and other polyomaviruses
IL286265A (en) A new tilapia virus and its uses
IL265833A (en) Novel hla hpv16 unrestricted t-cell compositions, compositions and methods for their use
IL267673A (en) Broad neutralizing antibodies against hiv-1 and methods of using them
IL272834A (en) Compositions of amantadine, their preparation, and methods of use
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
ZA201906326B (en) Analogs of deutetrabenazine, their preparation and use
IL258238B (en) Hiv antibody compositions and methods of use
PT3584252T (pt) Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
PT3390441T (pt) Anticorpos neutralizantes do vírus da imunodeficiência humana
GB201706600D0 (en) Virus preparations